



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

April 12, 2022

National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex
Bandra (E) Mumbai 400 051

Stock Symbol: JBCHEPHARM

Dear Sir,

Subject

- **Assignment of Trademark for Azmarda® indicated for heart failure patients with reduced ejection fraction (HfrEF) from Novartis AG, Switzerland for India**

Reference

- **Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

We refer to our letter dated April 1, 2022 intimating you about the approval by the Board of directors of the Company at its meeting held on April 1, 2022, for acquisition of the brand 'Azmarda' from Novartis AG, Switzerland. In compliance with Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we further wish to inform you that the aforesaid transaction of acquisition of the brand 'Azmarda' from Novartis AG, Switzerland has been successfully completed yesterday.

You are requested to take the same on record.

Thanking you,

Yours sincerely

For J. B. Chemicals & Pharmaceuticals Ltd.

Sandeep Phadnis
Vice President – Secretarial
& Company Secretary